In this issue:
Biosimilar trastuzumab has similar efficacy
Scalp cooling device reduces hair loss during chemotherapy
. . . and improves quality of life
Fulvestrant 500 mg vs anastrozole 1 mg in HR+ advanced disease
Post-chemotherapy cognitive complaints
T-DM1 vs trastuzumab + taxane in HER2+ advanced disease
Dose-dense chemotherapy in premenopausal disease
ABPI vs WBRT in low-risk breast cancer: 5-year data
Neoadjuvant carboplatin + docetaxel in TNBC
Adjusted BSA dosing regimen may reduce toxicity
Please login below to download this issue (PDF)